Intensive Nutrition in Critically Ill Adults

Overview

Despite the widespread use of nutrition therapy, no large scale randomized controlled trials (RCTs) have demonstrated positive outcomes with delivery of nutrition therapy early in critical illness, with some showing no effect with delayed nutrition or even harm. There are several possible reasons for the lack of observed benefit from RCTs to date; interventions have been short in duration (usually 3-10 days after intensive care unit (ICU) admission), perhaps applied at the incorrect time in regards to the patients metabolism and recovery, do not consider the patients nutrition risk, and have not addressed what happens to nutrition intake post ICU in critically ill individuals. This may explain why RCTs to date have not observed any positive associations with the delivery of nutrition; our focus to date may have been on the wrong stage of illness. A future study is thus urgently needed, which addresses the deficiencies in current RCTs by optimizing nutrition delivery for the whole hospital stay and collecting meaningful clinical, process and outcome data, which will potentially inform a larger trial of a similar nature. This initial study aims to determine whether optimization of energy using a pre-tested supplemental parenteral nutrition (PN) strategy in the Intensive Care Unit (ICU) and an intensive nutrition intervention in the post ICU period will deliver more total energy than standard nutrition care during hospital admission in a group of critically ill patients with at least one organ system failure.

Full Title of Study: “Intensive Nutrition Therapy Compared to Usual Care in Critically Ill Adults: A Randomised Pilot Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2022

Detailed Description

Background: Nutrition is a commonly provided therapy in critical illness, but data about effectiveness is sparse. Best practice guidelines recommend enteral nutrition (EN), a specialised solution delivered into the gastrointestinal tract, as the first line of nutrition therapy. The majority of best practice guidelines also recommend delivery of energy and protein amounts close to predicted requirements in critical illness over the course of Intensive Care Unit (ICU) admission, however the only evidence to support this is from observational data. Although recommended that energy and protein requirements be met, and observational data suggests this is of benefit, there are practical challenges with the provision of EN. International practice surveys report the average energy and protein provided is approximately 59% of the patients predicted requirements, for multifactorial reasons. The addition of parenteral (intravenous) nutrition has been proposed as a method to provide additional energy when EN is insufficient, termed supplemental parenteral nutrition (PN). The ability of this strategy to deliver additional energy and protein to patients during critical illness has been proven in several feasibility/pilot trials, but the benefit on clinical and functional outcomes is unknown. Despite observational data suggesting benefit when energy and protein delivery is optimised close to requirements, no large scale randomised controlled trials (RCTs) have confirmed improved clinical outcomes in critical illness, with some showing no effect with delayed nutrition or even harm. There are several possible reasons for the lack of observed benefit from RCTs to date; the interventions may have been applied at a time when the patient's metabolism is not in a phase of recovery; interventions have been short in duration and; studies have not addressed what happens to nutrition intake in the post ICU period of hospitalisation in critically ill individuals. Aims: To determine whether the use of a pre-tested supplemental PN strategy in the ICU and an intensive nutrition intervention after discharge to the hospital ward is feasible and will deliver more total energy than standard nutrition care over the entire hospital stay, in critically ill patients with at least one organ system failure. A further aim is to develop a research program that will determine whether optimisation of energy to critically ill patients over the entire period of hospitalisation improves clinically-meaningful outcomes. Hypothesis: In critically ill patients with at least one organ failure, the use of a supplemental PN strategy in ICU and an intensive nutrition intervention on the hospital ward will lead to an increase in daily energy delivery of at least 15% over the entire hospital stay when compared to standard care. Fifteen percent has been estimated as the minimum acceptable clinical difference between the two groups. Objectives: The major objectives are: 1. To determine whether the whole hospital nutrition intervention leads to increased amounts of total energy delivered over the period of hospital stay 2. To determine if the whole hospital nutrition intervention is safe in regards to adverse effects 3. To determine if the post-ICU nutrition intervention is practically feasible when applied in multiple hospitals, across multiple wards 4. To measure the clinical outcomes in patients and provide information to assist design of a larger randomised controlled trial

Interventions

  • Dietary Supplement: Supplemental parenteral nutrition
    • Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)

Arms, Groups and Cohorts

  • No Intervention: Standard Nutrition Arm
    • In ICU: After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required. PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops. Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm. After ICU: Nutrition management will be as per usual site management at that hospital. Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools.
  • Experimental: Intensive Arm
    • Intervention In ICU: Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol. After ICU: An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management.

Clinical Trial Outcome Measures

Primary Measures

  • Daily energy delivered from nutrition therapy
    • Time Frame: Day 28
    • Daily energy delivered from nutrition therapy

Secondary Measures

  • Nutrition intake
    • Time Frame: Day 28
    • Daily protein intake, Energy and protein intake by location (ICU and ward)
  • Duration hospital stay
    • Time Frame: Day 28
    • Duration of hospital stay in survivors and non-survivors
  • Ventilator Free Days
    • Time Frame: Day 28
    • Ventilator Free Days (VFDs) at study day 28
  • Total blood stream infection rate
    • Time Frame: Day 28
    • Total blood stream infection rate

Participating in This Clinical Trial

Inclusion criteria Patients in intensive care who meet all of the following will be eligible: 1. Admitted to intensive care between 72 hours and 120 hours 2. Receiving invasive ventilator support 3. At least 18 years of age 4. Have central venous access suitable for PN solution administration 5. Have 1 or more organ system failure (respiratory, cardiovascular or renal) related to their acute illness defined as:

  • PaO2/FiO2 ≤ 300 mmHg – Currently on 1 or more continuous inotrope/vasopressor infusion which were started at least 4 hours ago at a minimum dose of: 1. Noradrenaline ≥ 0.1mcg/kg/min 2. Adrenaline ≥ 0.1 mcg/kg/min 3. Any dose of vasopressin 4. Milrinone > 0.1 mcg/kg/min – Renal dysfunction defined as: 1. Serum creatinine 2.0-2.9 times baseline OR 2. Urine output 0.5ml/kg/hr for ≥ 12 hours OR 3. Currently receiving renal replacement therapy – Currently has an intracranial pressure monitor or ventricular drain in situ Exclusion criteria Patients will be excluded if: – Both EN and PN cannot be delivered at enrolment (i.e. either an enteral tube or a central venous catheter cannot be placed or clinicians feel that EN or PN cannot be safely administered due to any other reason) – Currently receiving PN – Clinician believes a specific parenteral formula is indicated – Death is imminent in the next 96 hours – There is a current treatment limitation in place or the patient is unlikely to survive to 6 months due to underlying/chronic illness – More than 80% of energy requirements have been satisfactorily delivered via the enteral route in the last 24 hours – Dialysis dependent chronic renal failure – Suspected or known pregnancy – Product contraindication – The treating clinician does not believe the study to be in the best interest of the patient

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Australian and New Zealand Intensive Care Research Centre
  • Collaborator
    • Baxter Healthcare Corporation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Emma Ridley, PhD, Principal Investigator, ANZIC-RC
  • Overall Contact(s)
    • Emma Ridley, PhD, +614399030350, emma.ridley@monash.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.